Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. Earlier this year, a peer-reviewed piece on an FDA-authorized clinical trial in Parkinson’s Disease was published by Wiley. Currently screening is underway for another Parkinson’s Disease trial, the seventh using Hope Bio’s cells to date, while detailed analysis continues on a completed Phase II trial that announced positive topline results. As we head into the fourth quarter of 2026, let’s take a look at what the Wiley piece says in plain language, wher

By Jan Shultis, Ph.D. As 2026 progresses, so, too, does research exploring Hope Biosciences’ proprietary cellular therapeutics in brain injury. Calendar year 2026 commenced with our cells at work in a Phase II clinical trial in Traumatic Brain Injury (TBI) executed by UTHealth Houston; early summer brought peer-reviewed publication in globe-leading neurology journal Brain of results of another TBI trial using our cells; and as summer presses on, we are delighted to begin manu

By Jan Shultis, Ph.D. During the last few weeks of 2025, Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) received Food and Drug Administration (FDA) authorization to administer Hope Biosciences’ allogeneic (donor) adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to seven men and women living with Multiple System Atrophy (MSA). As HBRF shared in their announcement, the occasion is noteworthy both for authorization of research i